RAPT Therapeutics is a clinical stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. Utilizing its proprietary drug discovery and development engine, the company develops highly selective small molecules that are designed to modulate the critical immune responses underlying these diseases. In its first four years since inception, RAPT has rapidly discovered and advanced two unique drug candidates each targeting CCR4 (C-C motif chemokine receptor 4). Our lead oncology drug candidate, FLX475, reached the clinic in just two and a half years and we expect our lead inflammation drug candidate, RPT193, to enter the clinic in the second half of 2019. The company is also pursuing a range of targets including GCN2 (general control nonderepressible 2) and HPK1 (hematopoietic progenitor kinase 1) for the treatment of cancer.